insights_auto
Pse është rritur NTLA 3,73%?
Zhytu më thellëchevron_right
NTLA:NASDAQ
Intellia Therapeutics Inc
13,07 US$
arrow_upward
+3,73%(+0,47) 1D
13,04 US$
arrow_downward
-0,22% (-0,028)bedtimeJashtë orarit
Mbyllur: 9 tet, 4:00:00 m.d., GMT-4 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për NTLA...
Hap
12,36 US$
I lartë
13,27 US$
I ulët
11,93 US$
Kapitalizimi i tregut
1,83 mld
Vëllimi mesatar
4,75 mln
Vëllimi
8,14 mln
Maksimumi 52-javor
28,24 US$
Minimumi 52-javor
7,95 US$
Fitimet për aksion
-3,36 US$
Beta
1,80
Aksionet në qarkullim
140,13 mln
Numri i punonjësve
377
Hap
12,36 US$
I lartë
13,27 US$
I ulët
11,93 US$
Kapitalizimi i tregut
1,83 mld
Vëllimi mesatar
4,75 mln
Vëllimi
8,14 mln
Maksimumi 52-javor
28,24 US$
Minimumi 52-javor
7,95 US$
Fitimet për aksion
-3,36 US$
Beta
1,80
Aksionet në qarkullim
140,13 mln
Numri i punonjësve
377
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Yahoo Finance
·
10 orë më parë
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?
Simply Wall Street
·
1 ditë më parë
Intellia Therapeutics (NTLA) Pullback Puts Its CRISPR Valuation Story Back In Focus
Profili
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Rreth Intellia Therapeutics Inc
Drejtori ekzekutivJohn Leonard
Punonjësit377
Themeluar më2014
SeliaKembrixh, Massachusetts, Shtetet e Bashkuara të Amerikës
Sektori-
Uebsajtiintelliatx.com